Status:
COMPLETED
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will assess the comfort of subcutaneous injections of NeoRecormon and darbepoetin alfa (Aranesp) in patients with renal anemia. Eligible patients will be randomized to receive comparable su...
Eligibility Criteria
Inclusion
- adult patients, \>18 years of age;
- patients with renal anemia or post-transplant anemia.
Exclusion
- poorly controlled hypertension;
- known hypersensitivity to NeoRecormon or darbepoetin alfa.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00377481
Start Date
September 1 2006
End Date
June 1 2007
Last Update
November 2 2016
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Adelaide, Australia, 5011
2
Gosford, Australia, 2250
3
Liverpool, Australia, 2170
4
Melbourne, Australia, 3168